STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours
- PMID: 39169716
- PMCID: PMC11602232
- DOI: 10.1111/his.15303
STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours
Abstract
Aims: STK11 adnexal tumour is a rare, recently described malignant neoplasm that is associated with Peutz-Jeghers syndrome. [Correction added on 3 October 2024, after first online publication: 'ST11' in preceding sentence has been corrected to 'STK11' in this version.] It predominantly originates from the para-adnexal soft tissues and often shows secondary involvement of the fallopian tube and ovary. STK11 adnexal tumours have a broad differential diagnosis due to their variable morphology and non-specific immunoprofile, and diagnostic confirmation currently requires sequencing to identify an STK11 mutation. We investigate the diagnostic utility of STK11 (LKB1) immunohistochemistry (IHC) in a cohort of STK11 adnexal tumours and morphological mimics.
Methods and results: IHC for STK11 was performed on 122 tumours, including 17 STK11 adnexal tumours and 105 morphological mimics (10 female adnexal tumours of Wolffian origin, 22 adult granulosa cell tumours, 10 juvenile granulosa cell tumours, four Sertoli-Leydig cell tumours, two Leydig cell tumours, one Sertoli cell tumour, one steroid cell tumour, four extra-ovarian sex cord-stromal tumours, 16 ovarian endometrioid carcinomas, eight tubo-ovarian high-grade serous carcinomas, five ovarian mesonephric-like adenocarcinomas, 14 ovarian carcinosarcomas, five peritoneal malignant mesotheliomas, two pelvic plexiform leiomyomata and one ovarian solid pseudopapillary tumour). All STK11 adnexal tumours showed complete loss of cytoplasmic staining for STK11. All other tumour types showed retained cytoplasmic staining, except for one endometrioid carcinoma with mucinous differentiation which showed complete loss of STK11 expression and a high-grade serous carcinoma with subclonal loss.
Conclusions: STK11 is a highly sensitive and specific immunohistochemical marker for distinguishing STK11 adnexal tumour from its histological mimics, and can obviate the need for confirmatory molecular studies in the appropriate morphological context.
Keywords: LKB1; STK11; STK11 adnexal tumour; fallopian tube; female adnexal tumour of Wolffian origin; ovary.
© 2024 John Wiley & Sons Ltd.
Conflict of interest statement
Disclosure/Conflict of Interest
The authors declare no conflict of interest.
References
-
- Bennett JA, Oliva E. The complex and often confusing history, histology and histogenesis of mesonephric, STK11 adnexal tumour and mesonephric-like neoplasms of the upper female genital tract (including broad ligament). Histopathology 2022;81;280–296. - PubMed
-
- Sharma AE, Slack JC, Parra-Herran CE et al. STK11 adnexal tumor in an adolescent female: Diagnostic pitfalls of a recently described entity. Pediatr Dev Pathol 2023;10935266231176681. - PubMed
-
- Calles A, Sholl LM, Rodig SJ et al. Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS-mutant lung adenocarcinoma. Clin Cancer Res 2015;21;2851–2860. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources